Seroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million ($70.7 million)

Contributed by: Business Wire

Tags

Finance

Neurology

Genetics

Clinical Trials

Professional Services

Biotechnology

Health

Pharmaceutical

Asset Management

Kurma Partners

More Like This

Seroba Announces Above Target Final Close of its Fund IV at €123M ($134M)

Samabriva is Set to Become a World Leader in Precision Biomanufacturing of Complex Molecules With the Announcement of a €4 Million Fundraising Round

Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups

Sequentia Biotech Secures €10million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for clinical, industrial and research applications (Graphic: Sequentia Biotech)

Sequentia Biotech Secures €10million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for Clinical, Industrial and Research Applications

MiLaboratories co-founders: Dmitry Chudakov, Stan Poslavsky, Dmitry Bolotin, Alexey Nechaev (Photo: Business Wire)

MiLaboratories Secures Series A, Raising Total Funding to $10 Million to Revolutionize the World of Genomic Research

Edward Kliphuis, Partner, Sofinnova Digital Medicine Strategy and Simon Turner, Partner, Sofinnova Digital Medicine Strategy (Photo: Sofinnova Partners)

Sofinnova Partners Raises $200M Digital Medicine Fund

PR Newswire associated0

Okomera Gets €1.5 Million Grant to Develop Microfluidics & AI Powered CRISPR Editing Platform for Target Validation

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs